-
Signature
-
/s/ David Watson, attorney-in-fact for Timothy Sullivan
-
Issuer symbol
-
APLS
-
Transactions as of
-
21 Oct 2025
-
Net transactions value
-
-$180,000
-
Form type
-
4
-
Filing time
-
23 Oct 2025, 16:20:30 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Sullivan Timothy Eugene |
Chief Financial Officer |
C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM |
/s/ David Watson, attorney-in-fact for Timothy Sullivan |
23 Oct 2025 |
0001707000 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
APLS |
Common Stock |
Options Exercise |
$100,300 |
+10,000 |
+9% |
$10.03 |
120,936 |
21 Oct 2025 |
Direct |
F1 |
| transaction |
APLS |
Common Stock |
Sale |
$280,300 |
-10,000 |
-8.3% |
$28.03 |
110,936 |
21 Oct 2025 |
Direct |
F1 |
| holding |
APLS |
Common Stock |
|
|
|
|
|
60,396 |
21 Oct 2025 |
The Timothy E Sullivan Irrevocable Trust of 2023 |
F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
APLS |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-10,000 |
-4.1% |
$0.000000 |
232,903 |
21 Oct 2025 |
Common Stock |
10,000 |
$10.03 |
Direct |
F1, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: